These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23298809)

  • 21. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
    Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
    Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
    Venkatraj M; Ariën KK; Heeres J; Joossens J; Dirié B; Lyssens S; Michiels J; Cos P; Lewi PJ; Vanham G; Maes L; Van der Veken P; Augustyns K
    Bioorg Med Chem; 2014 Oct; 22(19):5241-8. PubMed ID: 25199582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
    Ma XD; He QQ; Zhang X; Yang SQ; Yang LM; Gu SX; Zheng YT; Chen FE; Dai HF
    Eur J Med Chem; 2012 Dec; 58():504-12. PubMed ID: 23164656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Devale TL; Parikh J; Miniyar P; Sharma P; Shrivastava B; Murumkar P
    Bioorg Chem; 2017 Feb; 70():256-266. PubMed ID: 28160944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Murugesan V; Tiwari VS; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Makwana N; Suryawanshi R; Katti SB
    Bioorg Med Chem; 2011 Nov; 19(22):6919-26. PubMed ID: 21982685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
    Ekkati AR; Bollini M; Domaoal RA; Spasov KA; Anderson KS; Jorgensen WL
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1565-8. PubMed ID: 22269110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues.
    Ludovici DW; Kavash RW; Kukla MJ; Ho CY; Ye H; De Corte BL; Andries K; de Béthune MP; Azijn H; Pauwels R; Moereels HE; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Lewi PJ; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2229-34. PubMed ID: 11527704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
    Sergeyev S; Yadav AK; Franck P; Michiels J; Lewi P; Heeres J; Vanham G; Ariën KK; Vande Velde CM; De Winter H; Maes BU
    J Med Chem; 2016 Mar; 59(5):1854-68. PubMed ID: 26785139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
    Butini S; Brindisi M; Cosconati S; Marinelli L; Borrelli G; Coccone SS; Ramunno A; Campiani G; Novellino E; Zanoli S; Samuele A; Giorgi G; Bergamini A; Di Mattia M; Lalli S; Galletti B; Gemma S; Maga G
    J Med Chem; 2009 Feb; 52(4):1224-8. PubMed ID: 19170521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
    Wei L; Wang HL; Huang L; Chen CH; Morris-Natschke SL; Lee KH; Xie L
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2788-2792. PubMed ID: 28465101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-
    Yang Y; Kang D; Nguyen LA; Smithline ZB; Pannecouque C; Zhan P; Liu X; Steitz TA
    Elife; 2018 Jul; 7():. PubMed ID: 30044217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
    Udier-Blagović M; Tirado-Rives J; Jorgensen WL
    J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors.
    Čechová L; Dejmek M; Baszczyňski O; Šaman D; Gao L; Hu E; Stepan G; Jansa P; Janeba Z; Šimon P
    Antivir Chem Chemother; 2019; 27():2040206619826265. PubMed ID: 30788976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of NNRTIs on HIV reverse transcriptase dimerization.
    Tachedjian G; Goff SP
    Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Kang D; Fang Z; Li Z; Huang B; Zhang H; Lu X; Xu H; Zhou Z; Ding X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2016 Sep; 59(17):7991-8007. PubMed ID: 27541578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
    Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.